The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways
The DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chen, G., Bower, K. A., Ma, C., Fang, S., Thiele, C. J., & Luo, J. (2004) · The FASEB Journal · doi:10.1096/fj.04-1551fje · Cited by 310
RetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866 · cited 1×
“…signaling—Death domain-containing receptors, commonly called death receptors (DR), belong to the tumor necrosis factor (TNF) family of receptors that contain conserved intracellular death domains that are critical for the initiation of extrinsic apoptotic signaling (Ashkenazi and Dixit, 1998).”
BackgroundHengartner, M. O. (2000) · Nature · doi:10.1038/35037710 · Cited by 5,779
De Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,136
Phosphorylation meets ubiquitination: the control of NF-κB activity
Karin, M., & Ben-Neriah, Y. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.621 · Cited by 4,766
Identification of c- MYC as a Target of the APC Pathway
He, T.-C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · Science · doi:10.1126/science.281.5382.1509 · Cited by 4,566
Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis
Li, H., Zhu, H., Xu, C.-J., & Yuan, J. (1998) · Cell · doi:10.1016/s0092-8674(00)81590-1 · Cited by 4,445
Luo, X., Budihardjo, I., Zou, H., Slaughter, C., & Wang, X. (1998) · Cell · doi:10.1016/s0092-8674(00)81589-5 · Cited by 3,626 · cited 1×
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript cleavage of the BH3-only protein Bid, which then interacts with mitochondria to facilitate the release of mitochondrial proteins that promote apoptosis (Luo et al., 1998; Li et al., 1998).”
BackgroundTwo CD95 (APO‐1/Fas) signaling pathways
Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K., Krammer, P. H., & Peter, M. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.6.1675 · Cited by 3,000
Cited by
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768
Self-citationAkt signalling in health and disease
Hers, I., Vincent, E. E., & Tavaré, J. M. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.05.004 · Cited by 1,239
Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics
Jope, R. S., Yuskaitis, C. J., & Beurel, E. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9128-5 · Cited by 774
Self-citationLi, Z., Jo, J., Jia, J.-M., Lo, S.-C., Whitcomb, D. J., Jiao, S., Cho, K., & Sheng, M. (2010) · Cell · doi:10.1016/j.cell.2010.03.053 · Cited by 532
Wnt/Ca2+ signaling pathway: a brief overview
De, A. (2011) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmr079 · Cited by 523
GSK-3β, a pivotal kinase in Alzheimer disease
Llorens-MarÃtin, M., Jurado, J., Hernández, F., & Ãvila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451
Glycogen synthase kinase 3β (GSK3β) in tumorigenesis and cancer chemotherapy
Luo, J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.05.045 · Cited by 429
Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3)
Beurel, E., Michalek, S. M., & Jope, R. S. (2010) · Trends in Immunology · doi:10.1016/j.it.2009.09.007 · Cited by 378
Self-citationA novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.025 · Cited by 368
Role of Glycogen Synthase Kinase-3β in Cardioprotection
Juhaszova, M., Zorov, D. B., Yaniv, Y., Nuss, H. B., Wang, S., & Sollott, S. J. (2009) · Circulation Research · doi:10.1161/circresaha.109.197996 · Cited by 352
Li, Y., Ren, P., Dawson, A., Vasquez, H. G., Ageedi, W., Zhang, C., Luo, W., Chen, R., Li, Y., Kim, S., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046528 · Cited by 344
Is Glycogen Synthase Kinase-3 a Central Modulator in Mood Regulation?
Li, X., & Jope, R. S. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.105 · Cited by 294
“One of the most well-established properties of GSK3 inhibitors is their neuroprotective actions, as previously reviewed (Beurel and Jope, 2006; Chuang, 2005).”
Self-citationYuskaitis, C. J., & Jope, R. S. (2009) · Cellular Signalling · doi:10.1016/j.cellsig.2008.10.014 · Cited by 240
A Review of the Local Pathophysiologic Bases of Burn Wound Progression
Shupp, J. W., Nasabzadeh, T. J., Rosenthal, D. S., Jordan, M. H., Fidler, P., & Jeng, J. C. (2010) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e3181f93571 · Cited by 236
DaRocha-Souto, B., Coma, M., Pérez-Nievas, B. G., Scotton, T. C., Siao, M., Sánchez-Ferrer, P., Hashimoto, T., Fan, Z., Hudry, E., Barroeta, I., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.09.002 · Cited by 180
“In vitro and in vivo overexpression of GSK-3β has been shown to result in apoptotic neuronal cell death (reviewed in Beurel and Jope, 2006; Bhat et al., 2000b; Hetman et al., 2000; Lucas et al., 2001).”
Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits
Beurel, E., & Jope, R. S. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.129 · Cited by 92
Self-citationGlycogen synthase kinase-3 is an early determinant in the differentiation of pathogenic Th17 cells
Beurel, E., Yeh, W.-I., Michalek, S. M., Harrington, L. E., & Jope, R. S. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003511 · Cited by 86
Self-citationGSK3 and p53 - is there a link in Alzheimer's disease?
Proctor, C. J., & Gray, D. A. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-7 · Cited by 80
“A solution to this paradox is that GSK3 has a pro-apoptotic effect on the intrinsic pathway but an anti-apoptotic effect on the extrinsic pathway [4].”
BackgroundRegulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases
Beurel, E. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00018 · Cited by 82
Self-citationPerspectives for New and More Efficient Multifunctional Ligands for Alzheimer′s Disease Therapy
Zagórska, A., & Jaromin, A. (2020) · Molecules · doi:10.3390/molecules25153337 · Cited by 51
Vargas-Martínez, F., Uvnäs-Moberg, K., Petersson, M., Olausson, H. A., & Jiménez-Estrada, I. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.10.001 · Cited by 51
The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer
Borden, B. A., Baca, Y., Xiu, J., Tavora, F., Winer, I., Weinberg, B. A., Vanderwalde, A. M., Darabi, S., Korn, W. M., Mazar, A. P., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0497 · Cited by 15
Querfurth, H., Marshall, J., Parang, K., Rioult-Pedotti, M. S., Tiwari, R., Kwon, B., Reisinger, S., & Lee, H.-K. (2022) · PLOS ONE · doi:10.1371/journal.pone.0261696 · Cited by 9
Metadata
- Authors
- Beurel, E., & Jope, R. S.
- Venue
- Progress in Neurobiology
- Publisher
- Elsevier BV
- Published
- 2006-07
- Volume
- 79
- Issue
- 4
- Pages
- 173-189
- ISSN
- 0301-0082 (ISSN-L)
- OpenAlex
- W2055303877
- Cited by
- 541
- References
- 176
- FWCI
- 9.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.